Review/Advances in Neurological Therapeutics (2005). Peripheral Neuropathy.
|
Accession number;06A0654488
|
| Title;Review/Advances in Neurological Therapeutics (2005). Peripheral Neuropathy. |
| Author;
ARIMURA KIMIYOSHI
(Kagoshima Univ., JPN)
|
Journal Title;Neurological Therapeutics
|
Journal Code:X0110A
|
ISSN:0916-8443
|
|
VOL.23;NO.4;PAGE.395-398(2006)
|
| Figure&Table&Reference;REF.15 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;The literature on the treatment of neuropathy published in 2005 was reviewed. In Guillain-Barre syndrome, the efficacy of IVIG in children has been proven. In experimental allergic neuropathy, administration of the sodium channel blocker (flecainide) showed reduction in axonal degeneration. Since intractable immune-mediated neuropathies are closely correlated with secondary axonal damage, sodium channel blockers may be an expected alternative therapy in these cases. In chronic inflammatory demyelinating neuropathy, the efficacy of high-dose methylprednisolone therapy parallels that of IVIG or oral predinolone. In IVIG non-responders, an open trial study has shown cyclosporin to be an effective alternative therapy. A randomized control trial, however, will be needed. In hereditary neuropathy, administration of Neurotropin-3 produced improvement in neurological function as well as in nerve pathology in both animal models and patients with Charcot-Marie-Tooth disease 1A. In diabetic neuropathy, a multicenter RCT trial has demonstrated the efficacy of acetyl-L-carnitine on pain and improvement in vibration sensation as well as in pathological findings. Drug induced neuropathy secondary to platinum compounds, taxanes and vinca alkaroid in cancer patients were noted. Supplementation with vitamin E and acetyl-L-carnitine were effective in these patients. (author abst.) |
|
|
|
Related Articles;
|
|
